Senthil Sundaram, Terns CEO

Eli Lil­ly's transpa­cif­ic bo­som bud­dy Terns bags late-round fund­ing to dri­ve NASH hope­fuls through the clin­ic

In a hot mar­ket mar­ket for NASH, hav­ing big-name back­ers can help shine a spot­light on start­up play­ers look­ing to make a mark. That was cer­tain­ly the case for Terns Phar­ma­ceu­ti­cals and part­ner Eli Lil­ly, which pro­vid­ed seed fund­ing and li­censed three NASH can­di­dates to the ba­by biotech back in 2018.

Now, with two of those can­di­dates in the clin­ic, Terns has bagged new fund­ing to help speed to­ward the fin­ish line.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.